I am a Research Associate in Sleep and Dementia Neuroscience, working at the University of Bristol in the UK. I mainly work on feasibility studies trying to identify how we can study brain health and particularly sleep in older adults with mild cognitive impairment and dementia.

Dr Galvin is Professor of Neurology, chief of the Division of Cognitive Neurology and Director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine. He has published over 350 paper on cognitive aging, brain health and neurodegenerative disease. His research is funded by the NIH and numerous foundations.

Dr. Li Gan is director of the Helen and Robert Appel Alzheimer’s Disease Research Institute at Weill Cornell Medicine, where she is also the Burton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Diseases. Dr. Gan received Ph.D in cellular and molecular physiology from Yale University School of Medicine, and completed postdoctoral training at Harvard Medical School and the Gladstone Institute of Neurological Disease at the University of California, San Francisco (UCSF), where she was a senior investigator and associate director at Gladstone Institute of Neurological Disease, and professor of Neurology at UCSF before joining Weill Cornell Medicine in July 2018. Dr. Gan’s research focuses on innate immunity and proteostasis--the converging and interconnected pathways in such neurodegenerative diseases as Alzheimer's disease and frontotemporal dementia. Her lab discovered acetylation of tau as a new posttranslational mechanism underlying tau toxicity, identified maladaptive microglial mechanisms in neurodegeneration, and developed scalable neural iPSC-derived models widely used in the scientific community. Dr. Gan is recipient of Glenn Award in Aging Research, Alzheimer’s Association’s Inge Grundke-Iqbal Award for Alzheimer’s Research, and most recently the Helis Prize for Parkinson's Disease and Neurodegenerative research in 2022.

Dr. Thota Ganesh obtained his M.Sc. and Ph.D. in Organic chemistry from Osmania University, Hyderabad. INDIA. He did his postdoctoral studies at the University of Durham, England and Virginia Tech (USA). He is now an Associate Professor in the Department of Pharmacology and Chemical Biology at Emory University School of Medicine in Atlanta, GA. His current research interests are to develop therapeutic agents for treating epilepsy and Alzheimer’s disease. Dr. Ganesh has published well over 70 peer–reviewed scientific research articles. He has given several invited lectures in academic and pharma laboratories. Dr. Ganesh has 10 issued patents and 10 other patent applications in pending review. He received the INNOVATOR of the year award in 2018, and the HIDDEN-GEM award for 2020 at Emory University. He is a member of American Chemical Society, Society for Neuroscience, and he was a named scholar of Alzheimer’s Drug Discovery Foundation and Harrington Discovery Institute for 2013 and 2016. Dr. Ganesh serves in the journal editorial board and has received substantial funding from NIH to conduct research in medicinal chemistry and neuropharmacology areas. He is the recipient of the ASPET scientific achievement award from the division of drug discovery and development for 2023.

Focused on developing my knowledge in neuroscience, I combine my predoctoral studies with the coordination of multiple sclerosis clinical trials. My doctoral thesis aims to analyze the relationship between chronic treatments and the presence of Alzheimer's Disease. In parallel, I am dedicated to publishing popular science blogs to promote knowledge of the general population about cognitive impairment as a content creator for the DeCo Chair. I also organize pharmacy students who collaborate with us as content creators.

I’m currently Full Professor of Pharmacology at Dept. of Pharmacological and Biomolecular Sciences, University of Milano, Milano, Italy. I have established research lines focusing on the understanding of the molecular mechanisms regulating the efficacy the glutamatergic synapse in physiological conditions and the role of these events in neurodegenerative disorders. My lab of “Pharmacology of Neurodegeneration” at DiSFeB, University of Milano, has a validated expertise in several techniques including biochemistry, confocal imaging, molecular biology, use of in vitro and in vivo models of neurodegenerative disorders, i.e. FTD, Parkinson’s disease and Alzheimer’s Disease.

Hugo Geerts is Head Neuroscience Quantitative Systems Pharmacology (QSP) at Certara. His studies included a physics degree, a Biophysics PhD, a Bachelor Degree in Medicine, a Master in Pharmaceutical Sciences, and a Pharma Executive MBA. He worked for 17 years with Dr. Paul Janssen, the greatest drug hunter in history at the Janssen Research Foundation where he headed the Alzheimer Discovery research. He identified galantamine (Razadyne-Reminyl) for inlicensing and supported its successful clinical development in Alzheimer’s disease. In 2002, he co-founded In Silico Biosciences (ISB) to provide mechanistic disease modeling services in CNS R&D (notably schizophrenia, Alzheimer’s and Parkinson’s disease), providing support to over 15 companies. When ISB was acquired in 2020, he joined Certara-SimCyp to build out a comprehensive neuroscience QSP platform by combining advanced Physiology-Based PharmacoKinetic modeling with mechanism-based disease modeling. His passion is to get better drugs faster to the right patients by using translational computer modeling & simulation.

Hi! I am a 5th year PhD candidate in the Rousseaux Lab studying alpha-synuclein mislocalization in disease.

Dr. Angela Genge has been the Executive Director of the Clinical Research Unit at the Montreal at the Montreal Neurological Institute since 2004. Since 2020, she has also served as Chief Medical Officer for QurAlis and Scientific Director of CATALIS. Her expertise and ground-breaking work in the introduction of innovative therapies in the rare disease space has led her to be a sought-after member of numerous advisory boards for companies developing therapies for these diseases. Clinically, she is the Director of the Neuro ALS clinical program and multidisciplinary clinic, and a neuromuscular neurologist. Throughout her career she has received numerous awards, most recently the 2018 Forbes Norris Award, the DIVA of Distinction Award, and the Governor General Diamond Jubilee Award.

Jean Georges is the Executive Director of Alzheimer Europe. His role includes supporting the board, liaising with members and European organisations, and managing personnel, financial matters and overall project management. He also oversees the publication of Alzheimer Europe yearbooks and annual reports of ethical issues in dementia care, as well as the activities of the European Dementia Ethics Network. He has served as the Principal Investigator for Alzheimer Europe in projects supported by the Innovative Medicines Initiative and the European Union’s Research and Innovation Funding Programmes: FP7 and Horizon 2020. He also coordinated several multinational surveys on dementia care in Europe from the perspective of carers and members of the general public. Previously, he has served as the Secretary General of the European Federation of Neurological Associations (2002–2004), was a patient representative on the management board of the European Medicines Agency (2005–2008) and an Executive Committee Member of the European Patients’ Forum.

I am a second year PhD student at the University of Southampton under the supervision of Prof. Jessica Teeling and Dr Philip Williamson. I am currently working on better understanding the mechanisms behind cell-to-cell spreading of alpha-synuclein in the brain. Both my master’s and bachelor’s degrees were in Neuroscience at the University of Manchester. I’ve always had a keen interest in neurodegenerative diseases and dementia and the biological pathways that drive neuronal damage and memory loss. I am mostly intrigued by how inflammatory molecules and inflammatory responses are involved in the pathogenesis of nervous system disorders, especially in Parkinson’s Disease. Parkinson’s Disease is an incredibly debilitating disease affecting people globally. Therefore, the opportunity to contribute to research identifying possible mechanisms behind the disease pathology and therefore potentially identify a novel therapy target is of utmost importance to me.

I, Ruchi Gera, am working as a postdoctoral researcher in the group of Prof. Maria Eriksdotter, Division of Clinical Geriatrics, Dept. of Neurobiology, care sciences and society since 2020. I would like to briefly introduce myself. I completed my Ph.D. in Biological Sciences from CSIR-Indian Institute of Toxicology Research, India, 2018. I moved to Yale University, USA as a Postdoctoral Associate in the department of Immunobiology, to learn new techniques and expand my knowledge in the field of immunology. In 2020, I move to Sweden and since then I am working as a postdoctoral fellow in NVS department at Karolinska Institutet.